PRIMARY STUDY

Topical cannabis‐based medicines – A novel paradigm and treatment for non‐uremic calciphylaxis leg ulcers: An open label trial

Key Findings:  A team of physicians treated two female patients, whose painful leg ulcers failed to respond to all available best practices, with topical cannabis containing cannabinoids [THC (<1 mg/mL) and CBD (3.75 mg/mL) at a ~1:4 ratio], terpenes (beta-carophyllene), and flavonoids (quercetin, disomin, hersperidin). After an average of 76  days wounds closure was achieved in both patients with no adverse reactions. Additionally, after an average of of 63 days neither patient requirred any other analgesics